Multiple host range bacteriophage with different tail fibres
AssigneePhico Therapeutics Ltd.
InventorsHeather Fairhead, Adam Wilkinson, Emmanuele Severi, Neil Anderson, Katy Pitts, Anne Barnard
Life of this patent
Estimating the term…
Abstract
Modified bacteriophage and compositions containing the modified bacteriophage are described. Exemplary compositions are useful for human treatment and may treat various conditions, including bacterial infections.
Claims15
A modified bacteriophage capable of infecting a plurality of different target bacteria, which bacteriophage includes an α/β small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacteria;
- wherein the bacteriophage is non-lytic;
- wherein the bacteriophage expresses a plurality of different host range determinants;
- and wherein each host range determinant has a different bacterial host specificity, wherein each host range determinant comprises a tail fibre protein, wherein each host range determinant comprises a tail fibre protein which comprises a receptor binding region for binding to the target bacteria and a region linking the receptor binding region to the body of the bacteriophage, and wherein each tail fibre protein is from a Pseudomonas bacteriophage.
A modified bacteriophage capable of infecting a plurality of different target bacteria, wherein the bacteriophage expresses a plurality of different host range determinants each comprising a tail fibre which comprises a receptor binding region for binding to the target bacteria and a linking region that links the receptor binding region to the body of the bacteriophage, wherein each host range determinant has a different bacterial host specificity, and wherein the receptor binding region is a C-terminal receptor binding region and the region linking the C-terminal receptor binding region to the body of the bacteriophage is an N-terminal region, which bacteriophage includes an α/β small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacteria, wherein the N-terminal region comprises amino acids 1 to 628 of the tail fibre protein and the C-terminal region comprises amino acids 629 to 964 of the tail fibre protein, based on the amino acid sequence of bacteriophage Phi33, and/or wherein the C-terminal region has no more than 96% amino acid sequence identity with the C-terminal region of bacteriophage Phi33.
Dependencies are inferred from the claim text.